AUTHORS
Qingqing Cai, MD, Pengcheng He2, Yufu Li3, Tang Xiaoqiong4, Hui Wu5, Wei Yang6, Jie Cui, MD7, Haisheng Liu8, Mingxia Wang9, Huijing Wu10, Xinjun Liang11, Xu Wei, MD, PhD12, Yinfang Gu13, Qi Dang, MD14, Ji Ma, MD15, Fei Li, MD16, Caixia Sun, MD17, Peng Peng, PhD18, Shumao Ni19, Qing Li20, Hongchan Zhang21, Jean Fan, MD22, Jianyong Li, MD23
AFFILIATIONS
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
3 Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
4 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
5 Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian, China
6 Shengjing Hospital of China Medical University, Shenyang, China
7 Gansu Provincial Cancer Hospital, Lanzhou, China
8 Hebei Tumor Hospital, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
9 Hebei Tumor Hospital, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
10 Hubei Cancer Hospital, Hubei Cancer Research Institute, Affiliated Cancer Hospital of Tongji Medical College, Wuhan, China
11 Hubei Cancer Hospital, Hubei Cancer Research Institute, Affiliated Cancer Hospital of Tongji Medical College, Wuhan, China
12 Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
13 Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, China
14 Shandong Cancer Hospital, Jinan, China
15 Shandong Cancer Hospital, Jinan, China
16 The First Affiliated Hospital of Nanchang University, Nanchang, China
17 TransThera Sciences (Nanjing), Inc., Nanjing, China
18 TransThera Sciences (Nanjing), Inc., Nanjing, China
19 TransThera Sciences (Nanjing), Inc., Nanjing, China
20 TransThera Sciences (Nanjing), Inc., Nanjing, China
21 TransThera Sciences (Nanjing), Inc., Nanjing, China
22 TransThera Sciences (US),Inc., Gaithersburg, United States
23 Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
ABSTRACT
Background: Covalent BTK inhibitors (cBTKi) have transformed outcomes in relapsed/refractory (r/r) MCL, but sustained use is limited by acquired resistance and off-target toxicity. TT-01488 is a non-covalent, reversible BTK inhibitor that targets both wild-type and C481S-mutant BTK, a key resistance mechanism to cBTKi. We previously reported the preliminary antitumor activity and short-term safety of TT-01488 in patients (pts) with r/r MCL, including pts with cBTKi resistance (ASH 2025). Here, we present an updated analysis from the ongoing phase 1 study TT01488CN02 (NCT05683717).
Methods: Pts with r/r MCL, ≥1 prior therapy, ECOG PS 0-2, and adequate organ function were enrolled. Adverse events (AEs) were graded per CTCAE v5.0. Efficacy was evaluated per 2014 Lugano criteria.
Results: As of July 01, 2026, 35 r/r pts received TT-01488 at dose levels: 100mg QD (n=2), 150mg QD (n=13), 200mg QD (n=1), 100mg BID (n=19). The median age was 64 (range: 43-78); 85.7% were male. The median number of prior lines of therapy was 2.5 (range: 1-8); 54.3% had >2 lines. 97.1% of pts had received an anti-CD20 antibody, and 82.9% had received a cBTKi. Blastoid/pleomorphic variants comprised 17.1%.
All pts experienced treatment-related AEs (TRAEs). The most common TRAEs (≥20%) included hypertriglyceridemia, anemia, nausea, decreased appetite, vomiting, elevated transaminases, decreased platelet count, hyperuricaemia, asthenia, and neutropenia. Grade ≥3 TRAEs were observed in 17 pts, most frequently hypertriglyceridemia (28.6%), neutropenia (14.3%), and increased gamma-glutamyltransferase (5.7%). No fatal TRAEs occurred. Notably, no drug-related atrial fibrillation/flutter was observed.
At a median follow-up of 11.8 months, among 29 efficacy-evaluable pts, the overall response rate (ORR) was 48.3% (14/29), with a complete response (CR) rate of 31% (9/29). In non-blastoid pts with prior cBTKi exposure, ORR was 50% (10/20); in the 100mg BID dose group, ORR reached 60% (6/10). Progression-free survival (PFS) in non-blastoid MCL was 6.4 months (95% CI, 1.9-NE), and duration of response (DOR) was 20.3 months (95% CI, 1.9-NE). Sustained pBTK C481S mutant inhibition ( >90%) at steady state was observed at doses of 100mg QD and above.
Conclusion: TT-01488 shows promising efficacy and manageable safety in r/r MCL, consistent with prior findings. Beyond the salvage setting, reversible BTK inhibitors maintain target inhibition without covalent binding, improve kinase selectivity, and reduce off-target toxicity, supporting a favorable long-term safety profile. These features warrant investigation in earlier-line combinations to achieve deep, durable remissions. Our data support continued development of TT-01488 in BTKi-resistant MCL and provide a foundation for front-line combination trials.
DISCLOSURES
Jean Fan, MD: TransThera Sciences (US), Inc - Current equity holder in publicly-traded company; TransThera Sciences (US), Inc - Current Employment